Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice

被引:43
作者
Deng, CX [1 ]
机构
[1] NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA
关键词
Brca1; p53; centrosome; G(2)-M checkpoint; tumorigenesis;
D O I
10.1016/S0027-5107(01)00119-1
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Germline mutations in Brca1 are responsible for most cases of familial breast and ovarian cancers, but somatic mutations in the gene are rarely detected in sporadic rumors. Moreover, mouse embryos carrying Brca1-null mutations or homozygous deletions of Brca1 exon 11 of (Brca1(Delta 11/Delta 11)) die during gestation due to proliferation defects, raising questions about the mechanisms by which Brca1 represses tumor formation. Molecular analysis reveals that these Brca1 mutations cause hypersensitivity to gamma -irradiation and chromosomal abnormalities in embryos and embryonic fibroblast cells (MEFs). Notably, Brca1(Delta 11/Delta 11) MEFs maintain an intact G(1)-S checkpoint, but are defective in G(2)-M checkpoint control. They also contain multiple, functional centrosomes, which lead to unequal chromosome segregation and aneuploidy. These data uncover an essential role for Brca1 in maintaining genetic stability through regulation of centrosome duplication and G(2)-M checkpoint, and provide a molecular basis for its role in tumorigenesis. Finally, we show that conditional mutation of Brca1 in mammary epithelium causes increased apoptosis and abnormal ductal development. Mammary tumor formation in mutant mice occurs after long latency and is associated with p53 mutations. These results are consistent with a model that Brca1 acts as a caretaker gene, whose absence does not directly initiate tumorigenesis, instead, causes genetic instability, which triggers further alterations and ultimately leads to tumor formation. Published by Elsevier Science B.V.
引用
收藏
页码:183 / 189
页数:7
相关论文
共 58 条
  • [1] Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003
  • [2] BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963
  • [3] The second BRCT domain of BRCA-1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter
    Chai, YL
    Cui, JQ
    Shao, NS
    Reddy, ESP
    Rao, VN
    [J]. ONCOGENE, 1999, 18 (01) : 263 - 268
  • [4] A problem from integral geometry
    Chapman, R
    [J]. SIAM REVIEW, 1996, 38 (04) : 678 - 679
  • [5] Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells
    Chen, JJ
    Silver, DP
    Walpita, D
    Cantor, SB
    Gazdar, AF
    Tomlinson, G
    Couch, FJ
    Weber, BL
    Ashley, T
    Livingston, DM
    Scully, R
    [J]. MOLECULAR CELL, 1998, 2 (03) : 317 - 328
  • [6] Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1
  • [7] p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours
    Crook, T
    Brooks, LA
    Crossland, S
    Osin, P
    Barker, KT
    Waller, J
    Philp, E
    Smith, PD
    Yulug, I
    Peto, J
    Parker, G
    Allday, MJ
    Crompton, MR
    Gusterson, BA
    [J]. ONCOGENE, 1998, 17 (13) : 1681 - 1689
  • [8] p53 mutations in BRCA1-associated familial breast cancer
    Crook, T
    Crossland, S
    Crompton, MR
    Osin, P
    Gusterson, BA
    [J]. LANCET, 1997, 350 (9078) : 638 - 639
  • [9] Cui JQ, 1998, ONCOL REP, V5, P585
  • [10] Cui JQ, 1998, ONCOL REP, V5, P591